BACKGROUND: This study aimed to evaluate the association of recurrent molecular alterations in prostate cancer, such as ERG rearrangements and phosphatase and tensin homolog gene (PTEN) deletions, with oncologic outcomes in patients with prostate cancer treated with brachytherapy. METHODS: Ninety-two men underwent I-125 brachytherapy with a 145 Gy delivered dose between 2000 and 2008. Pretreatment prostate biopsies were analyzed by immunohistochemistry (IHC) and FISH for ERG rearrangement and overexpression, PTEN deletion, and expression loss. Univariable and multivariable Cox-regression analyses evaluated association of ERG and PTEN status with biochemical recurrence (BCR). RESULTS: Within a median follow-up of 73 months, 11% of patients experienced BCR. Of 80 samples with both IHC and FISH performed for ERG, 46 (57.8%) demonstrated rearrangement by FISH and 45 (56.3%) by IHC. Of 77 samples with both IHC and FISH for PTEN, 14 (18.2%) had PTEN deletion by FISH and 22 (28.6%) by IHC. No significant associations were found between ERG, PTEN status, and clinicopathologic features. Patients with concurrent ERG rearrangement and PTEN deletion demonstrated significantly worse relapse-free survival rates compared with those with ERG or PTEN wild type (P < 0.01). In multivariable Cox regression analysis adjusted for the effects of standard clinicopathologic features, combined ERG rearranged and PTEN deletion was independently associated with BCR (HR = 2.6; P = 0.02). CONCLUSIONS: Concurrent ERG rearrangement and PTEN loss was independently associated with time to BCR in patients undergoing brachytherapy. Future studies are needed to validate prostate cancer molecular subtyping for risk stratification. IMPACT: Identifying patients in the ERG-rearranged/PTEN-deleted molecular subclass may improve treatment personalization.
BACKGROUND: This study aimed to evaluate the association of recurrent molecular alterations in prostate cancer, such as ERG rearrangements and phosphatase and tensin homolog gene (PTEN) deletions, with oncologic outcomes in patients with prostate cancer treated with brachytherapy. METHODS: Ninety-two men underwent I-125 brachytherapy with a 145 Gy delivered dose between 2000 and 2008. Pretreatment prostate biopsies were analyzed by immunohistochemistry (IHC) and FISH for ERG rearrangement and overexpression, PTEN deletion, and expression loss. Univariable and multivariable Cox-regression analyses evaluated association of ERG and PTEN status with biochemical recurrence (BCR). RESULTS: Within a median follow-up of 73 months, 11% of patients experienced BCR. Of 80 samples with both IHC and FISH performed for ERG, 46 (57.8%) demonstrated rearrangement by FISH and 45 (56.3%) by IHC. Of 77 samples with both IHC and FISH for PTEN, 14 (18.2%) had PTEN deletion by FISH and 22 (28.6%) by IHC. No significant associations were found between ERG, PTEN status, and clinicopathologic features. Patients with concurrent ERG rearrangement and PTEN deletion demonstrated significantly worse relapse-free survival rates compared with those with ERG or PTEN wild type (P < 0.01). In multivariable Cox regression analysis adjusted for the effects of standard clinicopathologic features, combined ERG rearranged and PTEN deletion was independently associated with BCR (HR = 2.6; P = 0.02). CONCLUSIONS: Concurrent ERG rearrangement and PTEN loss was independently associated with time to BCR in patients undergoing brachytherapy. Future studies are needed to validate prostate cancer molecular subtyping for risk stratification. IMPACT: Identifying patients in the ERG-rearranged/PTEN-deleted molecular subclass may improve treatment personalization.
Authors: Sumin Han; J Chad Brenner; Aaron Sabolch; Will Jackson; Corey Speers; Kari Wilder-Romans; Karen E Knudsen; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng Journal: Neoplasia Date: 2013-10 Impact factor: 5.715
Authors: Frank Peinemann; Ulrich Grouven; Lars G Hemkens; Carmen Bartel; Holger Borchers; Michael Pinkawa; Axel Heidenreich; Stefan Sauerland Journal: Cochrane Database Syst Rev Date: 2011-07-06
Authors: Alcides Chaux; Roula Albadine; Antoun Toubaji; Jessica Hicks; Alan Meeker; Elizabeth A Platz; Angelo M De Marzo; George J Netto Journal: Am J Surg Pathol Date: 2011-07 Impact factor: 6.394
Authors: Akash Kumar; Thomas A White; Alexandra P MacKenzie; Nigel Clegg; Choli Lee; Ruth F Dumpit; Ilsa Coleman; Sarah B Ng; Stephen J Salipante; Mark J Rieder; Deborah A Nickerson; Eva Corey; Paul H Lange; Colm Morrissey; Robert L Vessella; Peter S Nelson; Jay Shendure Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley Journal: N Engl J Med Date: 2011-01-05 Impact factor: 91.245
Authors: Frank Peinemann; Ulrich Grouven; Carmen Bartel; Stefan Sauerland; Holger Borchers; Michael Pinkawa; Axel Heidenreich; Stefan Lange Journal: Eur Urol Date: 2011-06-29 Impact factor: 20.096
Authors: Alberto Briganti; Steven Joniau; Paolo Gontero; Firas Abdollah; Niccolò M Passoni; Bertrand Tombal; Giansilvio Marchioro; Burkhard Kneitz; Jochen Walz; Detlef Frohneberg; Chris H Bangma; Markus Graefen; Alessandro Tizzani; Bruno Frea; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn Journal: Eur Urol Date: 2011-12-02 Impact factor: 20.096
Authors: Tamara L Lotan; Bora Gurel; Siobhan Sutcliffe; David Esopi; Wennuan Liu; Jianfeng Xu; Jessica L Hicks; Ben H Park; Elizabeth Humphreys; Alan W Partin; Misop Han; George J Netto; William B Isaacs; Angelo M De Marzo Journal: Clin Cancer Res Date: 2011-08-30 Impact factor: 12.531
Authors: Manuel S Eisenberg; R Jeffrey Karnes; Dharam Kaushik; Laureano Rangel; Eric J Bergstralh; Stephen A Boorjian Journal: J Urol Date: 2013-05-29 Impact factor: 7.450
Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan Journal: Prostate Date: 2015-07-14 Impact factor: 4.104
Authors: Deli Liu; Michael A Augello; Ivana Grbesa; Davide Prandi; Yang Liu; Jonathan E Shoag; R Jeffrey Karnes; Bruce J Trock; Eric A Klein; Robert B Den; Francesca Demichelis; Elai Davicioni; Andrea Sboner; Christopher E Barbieri Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan Journal: Nat Rev Urol Date: 2018-02-20 Impact factor: 14.432
Authors: Kanerva Lahdensuo; Andrew Erickson; Irena Saarinen; Heikki Seikkula; Johan Lundin; Mikael Lundin; Stig Nordling; Anna Bützow; Hanna Vasarainen; Peter J Boström; Pekka Taimen; Antti Rannikko; Tuomas Mirtti Journal: Mod Pathol Date: 2016-08-26 Impact factor: 7.842
Authors: Tamara L Lotan; Wei Wei; Carlos L Morais; Sarah T Hawley; Ladan Fazli; Antonio Hurtado-Coll; Dean Troyer; Jesse K McKenney; Jeffrey Simko; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; James D Brooks Journal: Eur Urol Focus Date: 2016-06